Study Evaluating Venlafaxine ER in Adults With Panic Disorder
NCT00038896
Last updated date
ABOUT THIS STUDY
The primary objective of this study is to determine the efficacy, safety, and tolerability of
a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in
the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III
study.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Panic Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- A male or female outpatient
- Be at least 18 years of age and legal age of consent
- Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Treatment with venlafaxine (IR or ER) within 6 months of study day 1
- Known hypersensitivity to venlafaxine (IR or ER) or related compounds
- History or presence of any clinically important hepatic, renal, or other medical
disease that might compromise the study or be detrimental to the patient (eg,
clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal
cell epithelioma], uncontrolled hypertension)
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Panic DisorderA Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients
NCT00198094
- Tampa, Florida
- Indianapolis, Indiana
- Philadelphia, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Panic DisorderStudy Evaluating Venlafaxine ER in Adults With Panic Disorder
NCT00038896
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Panic DisorderA Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
NCT00677352
- Nagoya, Aichi
- Fukuoka-shi, Fukuoka
- Kitakyushu-shi, Fukuoka
- Kitakyusyu-shi, Fukuoka
- Sapporo-Shi, Hokkaido
- Sapporo, Hokkaido
- Higashiibaraki-gun, Ibaraki
- Fujisawa-city, Kanagawa
- Sagamihara-Shi, Kanagawa
- Yokohama-Shi, Kanagawa
- Yokohama, Kanagawa
- Kawaguchi-shi, Saitama
- Saitama city, Saitama
- Chiyoda-ku, Tokyo
- Kita-ku, Tokyo
- Minato-ku, Tokyo
- Musashino, Tokyo
- Nakano-Ku, Tokyo
- Nakanoku, Tokyo
- Setagaya-ku, Tokyo
- Shinjuku-ku, Tokyo
- Toshima-ku, Tokyo
- Nakano-ku, Yokohama
- Minato-ku,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Panic DisorderStudy Evaluating Venlafaxine ER in Patients With Panic Disorder
NCT00044772
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Study Evaluating Venlafaxine ER in Adults With Panic Disorder | |||
| Official Title ICMJE | A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder | |||
| Brief Summary | The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III study. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Primary Purpose: Treatment | |||
| Condition ICMJE | Panic Disorder | |||
| Intervention ICMJE | Drug: Venlafaxine ER | |||
| Study Arms ICMJE | Not Provided | |||
| Publications * | Liebowitz MR, Asnis G, Mangano R, Tzanis E. A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry. 2009 Apr;70(4):550-61. Epub 2009 Apr 7. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 343 | |||
| Original Enrollment ICMJE | Not Provided | |||
| Actual Study Completion Date ICMJE | December 2002 | |||
| Actual Primary Completion Date | December 2002 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Not Provided | |||
| Removed Location Countries | Canada, United States | |||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00038896 | |||
| Other Study ID Numbers ICMJE | 0600B5-353 | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Not Provided | |||
| Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Verification Date | August 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||